The latest orphan drug exemptions may not be warranted, analysis finds | STAT
statnews.com · 237 words · saved by 1 readers
A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.
By Ed Silverman Aug. 4, 2026 Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. A controversial provision in the One Big Beautiful Bill Act, which exempts more so-called orphan drugs from Medicare pricing negotiations in order to encourage further development, may not warrant that protection, according to a new analysis. At issue is a portion of the Inflation…
saved by
related reading
- Access granted: CMS greenlights more than 150 participants for chronic care experimentstatnews.com
- Why fixing the IRA matters to all of us - RApportrapport.bio
- Joe Biden Lowered Drug Prices. Does Anyone Care? - The Atlantictheatlantic.com
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- Eroom's law - Wikipediaen.wikipedia.org
- Rare Diseases at FDA | FDAfda.gov
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
- 曾是聯合國認可的罕病人權大國，為何台灣今讓患者淪落健保邊緣人？ - 報導者 The Reportertwreporter.org
- The Secret Gamble at the FDA That Exposed Americans to Risky Drugs — ProPublicapropublica.org
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Why kid-friendly medications can be expensive for parentspbs.org
- TrumpRxtrumprx.gov